Stock Events

Stock Events

VYNE Therapeutics 

$28.56
54
+$3.11+12.22% Monday 20:00
+$0.32+1.12%Monday 23:48After hours

Statistics

Day High
28.56
Day Low
23.37
52W High
46.95
52W Low
14.03
Volume
93,256
Avg. Volume
17,177
Mkt Cap
19.07M
P/E Ratio
-
Dividend Yield
2.74%
Dividend
0.78

Upcoming

21
JUL 27
Dividend Ex
Estimated
 
23
JUL 27
Dividend Payment
Estimated
 
23
JUL 27
Dividend Payment
Estimated
 
26
JUL 27
Dividend Ex
Estimated
 
21
JUL 28
Dividend Ex
Estimated
 

Dividends

2.74%Dividend Yield
Jul 26
$0.38
Jul 26
$0.40
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-9
-6.04
-3.09
-0.13
Expected EPS
-9
Actual EPS
N/A

Financials

-4,646.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
570,000Revenue
-26.48MNet Income

Analyst Ratings

0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VYNE. It's not an investment recommendation.
Apple
6
AAPL
Bionano Genomics
6
BNGO
NIO
5
NIO
Fuelcell Energy
5
FCEL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biotech company that develops treatments in areas similar to VYNE, including dermatology and inflammatory diseases.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie competes in the dermatology space with its portfolio of drugs, directly challenging VYNE's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the dermatological and autoimmune sectors against VYNE.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad range of products that include treatments for conditions VYNE targets, making them a direct competitor.
Merck
MRK
Mkt Cap305.12B
Merck operates in similar therapeutic areas as VYNE, including anti-inflammatory and dermatological conditions.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences focuses on inflammatory and respiratory diseases, competing with VYNE's product offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals specializes in biopharmaceuticals for dermatology, directly competing with VYNE.
Novartis
NVS
Mkt Cap293.94B
Novartis offers products in dermatology and chronic diseases, areas where VYNE is also active.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb has a diverse portfolio that includes treatments for immune-mediated diseases, competing with VYNE.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca has a focus on respiratory, cardiovascular, and autoimmune diseases, overlapping with VYNE's focus areas.

About

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Show more...
CEO
Mr. David T. Domzalski
Employees
10
Country
United States
ISIN
US92941V2097

Listings

NASDAQ
US
VYNE
XNAS
US
YARW
BOATS
BOATS
VYNE.BOATS

0 Comments

Share your thoughts

FAQ

What is VYNE Therapeutics stock price today?▼
The current price of VYNE is $28.56 USD — it has increased by +12.22% in the past 24 hours. Watch VYNE Therapeutics stock price performance more closely on the chart.
What is VYNE Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange VYNE Therapeutics stocks are traded under the ticker VYNE.
Is VYNE Therapeutics stock price growing?▼
VYNE stock has fallen by -38.11% compared to the previous week, the month change is a -12.26% fall, over the last year VYNE Therapeutics has showed a +43.52% increase.
What is VYNE Therapeutics market cap?▼
Today VYNE Therapeutics has the market capitalization of 19.07M
When is the next VYNE Therapeutics earnings date?▼
VYNE Therapeutics is going to release the next earnings report on August 19, 2026.
What is VYNE Therapeutics revenue for the last year?▼
VYNE Therapeutics revenue for the last year amounts to 570,000 USD.
What is VYNE Therapeutics net income for the last year?▼
VYNE net income for the last year is -26.48M USD.
Does VYNE Therapeutics pay dividends?▼
Yes, VYNE dividends are paid en. The last dividend per share was 0.38 USD. As of today, Dividend Yield (FWD)% is 2.74%.
How many employees does VYNE Therapeutics have?▼
As of July 30, 2026, the company has 10 employees.
In which sector is VYNE Therapeutics located?▼
VYNE Therapeutics operates in the Health & Wellness sector.
When did VYNE Therapeutics complete a stock split?▼
The last stock split for VYNE Therapeutics was on February 13, 2023 with a ratio of 1:18.
Where is VYNE Therapeutics headquartered?▼
VYNE Therapeutics is headquartered in Stewartsville, United States.